Drug interactions
Elacestrant + Lapatinib
Severity: Moderate
Elacestrant and Lapatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Elacestrant is metabolized mainly by CYP3A4, and lapatinib can weakly to moderately inhibit this enzyme. Raised elacestrant levels may increase its adverse effects, such as nausea, lipid abnormalities and musculoskeletal pain.
What this interaction means in plain words
Elacestrant and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Elacestrant belongs to Oncology; Lapatinib belongs to Oncology.
Why it happens
CYP3A4 inhibition by lapatinib reduces elacestrant metabolism.
What to do
Monitor for elacestrant adverse effects. Consider an alternative to lapatinib if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elacestrant and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Other interactions of Elacestrant
Frequently asked questions
Can I take Elacestrant with Lapatinib?
MediHelp rates the interaction as moderate. Elacestrant and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Elacestrant is metabolized mainly by CYP3A4, and lapatinib can weakly to moderately inhibit this enzyme. Raised elacestrant levels may increase its adverse effects, such as nausea, lipid abnormalities and musculoskeletal pain.
How serious is the interaction between Elacestrant and Lapatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for elacestrant adverse effects. Consider an alternative to lapatinib if toxicity occurs.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
